EP4271213A4 - COMPOSITIONS AND METHODS OF SUBLINGUAL ADMINISTRATION OF NICOTINE - Google Patents
COMPOSITIONS AND METHODS OF SUBLINGUAL ADMINISTRATION OF NICOTINE Download PDFInfo
- Publication number
- EP4271213A4 EP4271213A4 EP23723800.1A EP23723800A EP4271213A4 EP 4271213 A4 EP4271213 A4 EP 4271213A4 EP 23723800 A EP23723800 A EP 23723800A EP 4271213 A4 EP4271213 A4 EP 4271213A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- nicotine
- compositions
- methods
- sublingual administration
- sublingual
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
- A24B—MANUFACTURE OR PREPARATION OF TOBACCO FOR SMOKING OR CHEWING; TOBACCO; SNUFF
- A24B15/00—Chemical features or treatment of tobacco; Tobacco substitutes, e.g. in liquid form
- A24B15/10—Chemical features of tobacco products or tobacco substitutes
- A24B15/16—Chemical features of tobacco products or tobacco substitutes of tobacco substitutes
-
- A—HUMAN NECESSITIES
- A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
- A24B—MANUFACTURE OR PREPARATION OF TOBACCO FOR SMOKING OR CHEWING; TOBACCO; SNUFF
- A24B13/00—Tobacco for pipes, for cigars, e.g. cigar inserts, or for cigarettes; Chewing tobacco; Snuff
-
- A—HUMAN NECESSITIES
- A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
- A24B—MANUFACTURE OR PREPARATION OF TOBACCO FOR SMOKING OR CHEWING; TOBACCO; SNUFF
- A24B15/00—Chemical features or treatment of tobacco; Tobacco substitutes, e.g. in liquid form
- A24B15/18—Treatment of tobacco products or tobacco substitutes
-
- A—HUMAN NECESSITIES
- A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
- A24B—MANUFACTURE OR PREPARATION OF TOBACCO FOR SMOKING OR CHEWING; TOBACCO; SNUFF
- A24B15/00—Chemical features or treatment of tobacco; Tobacco substitutes, e.g. in liquid form
- A24B15/18—Treatment of tobacco products or tobacco substitutes
- A24B15/28—Treatment of tobacco products or tobacco substitutes by chemical substances
-
- A—HUMAN NECESSITIES
- A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
- A24B—MANUFACTURE OR PREPARATION OF TOBACCO FOR SMOKING OR CHEWING; TOBACCO; SNUFF
- A24B15/00—Chemical features or treatment of tobacco; Tobacco substitutes, e.g. in liquid form
- A24B15/18—Treatment of tobacco products or tobacco substitutes
- A24B15/28—Treatment of tobacco products or tobacco substitutes by chemical substances
- A24B15/30—Treatment of tobacco products or tobacco substitutes by chemical substances by organic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/465—Nicotine; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Toxicology (AREA)
- Inorganic Chemistry (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US17/700,646 US20230301341A1 (en) | 2022-03-22 | 2022-03-22 | Compositions and methods for sublingual delivery of nicotine |
| US17/700,628 US11700875B1 (en) | 2022-03-22 | 2022-03-22 | Compositions and methods for sublingual delivery of nicotine |
| PCT/US2023/015626 WO2023183227A1 (en) | 2022-03-22 | 2023-03-20 | Compositions and methods for sublingual delivery of nicotine |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EP4271213A1 EP4271213A1 (en) | 2023-11-08 |
| EP4271213A4 true EP4271213A4 (en) | 2024-08-28 |
Family
ID=88069090
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP23723800.1A Withdrawn EP4271213A4 (en) | 2022-03-22 | 2023-03-20 | COMPOSITIONS AND METHODS OF SUBLINGUAL ADMINISTRATION OF NICOTINE |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP4271213A4 (en) |
| JP (2) | JP2024514732A (en) |
| AU (1) | AU2023238723A1 (en) |
| CA (1) | CA3196913A1 (en) |
| MX (1) | MX2023009659A (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE540813C2 (en) * | 2017-04-24 | 2018-11-20 | Swedish Match North Europe Ab | A flavoured moist oral pouched nicotine product comprising |
| WO2018233795A1 (en) * | 2017-06-23 | 2018-12-27 | Fertin Pharma A/S | NICOTINE POCKET |
| WO2020244721A1 (en) * | 2019-06-07 | 2020-12-10 | Ncp Nextgen A/S | Nicotine pouch composition and pouch comprising such |
| US20210345656A1 (en) * | 2017-12-08 | 2021-11-11 | Fertin Pharma A/S | High nicotine absorption |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018197454A1 (en) * | 2017-04-24 | 2018-11-01 | Swedish Match North Europe Ab | A flavoured moist oral pouched nicotine product comprising triglyceride |
| AU2019256805B2 (en) * | 2018-04-16 | 2022-03-03 | Poviva Corp. | Compositions infused with nicotine compounds and methods of use thereof |
| BR112022024943A2 (en) * | 2020-06-08 | 2022-12-27 | Nicoventures Trading Ltd | EFERVESCENT ORAL COMPOSITION COMPRISING AN ACTIVE INGREDIENT |
-
2023
- 2023-03-20 EP EP23723800.1A patent/EP4271213A4/en not_active Withdrawn
- 2023-03-20 AU AU2023238723A patent/AU2023238723A1/en active Pending
- 2023-03-20 JP JP2023532289A patent/JP2024514732A/en active Pending
- 2023-03-20 MX MX2023009659A patent/MX2023009659A/en unknown
- 2023-03-20 CA CA3196913A patent/CA3196913A1/en active Pending
-
2025
- 2025-10-01 JP JP2025165086A patent/JP2025178423A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE540813C2 (en) * | 2017-04-24 | 2018-11-20 | Swedish Match North Europe Ab | A flavoured moist oral pouched nicotine product comprising |
| WO2018233795A1 (en) * | 2017-06-23 | 2018-12-27 | Fertin Pharma A/S | NICOTINE POCKET |
| US20210345656A1 (en) * | 2017-12-08 | 2021-11-11 | Fertin Pharma A/S | High nicotine absorption |
| WO2020244721A1 (en) * | 2019-06-07 | 2020-12-10 | Ncp Nextgen A/S | Nicotine pouch composition and pouch comprising such |
Non-Patent Citations (1)
| Title |
|---|
| See also references of WO2023183227A1 * |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2025178423A (en) | 2025-12-05 |
| AU2023238723A1 (en) | 2024-08-15 |
| EP4271213A1 (en) | 2023-11-08 |
| MX2023009659A (en) | 2023-10-13 |
| JP2024514732A (en) | 2024-04-03 |
| CA3196913A1 (en) | 2023-09-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP4090674A4 (en) | METHODS AND COMPOSITIONS OF BIASED IL2 MUTEINS | |
| EP4346788A4 (en) | ENANTIOMERIC ENTACTOGENIC COMPOSITIONS AND METHODS OF USE THEREOF | |
| MA71697A (en) | COMPOSITIONS AND METHODS FOR INHIBITING KRAS | |
| EP4308556A4 (en) | AMINOHETEROARYL COMPOUNDS AND COMPOSITIONS | |
| EP4121022A4 (en) | COMPOSITIONS AND METHODS FOR THE TREATMENT AND PREVENTION OF CORONAVIRUS INFECTION | |
| EP4313002A4 (en) | POLYNUCLEOTIDE COMPOSITIONS, RELATED FORMULATIONS AND METHODS OF USE THEREOF | |
| EP4284417A4 (en) | COMPOSITIONS AND METHODS OF TREATMENT OF HEREDITARY ANGIEDEMA | |
| EP4271213A4 (en) | COMPOSITIONS AND METHODS OF SUBLINGUAL ADMINISTRATION OF NICOTINE | |
| IL315052A (en) | Compositions of hydroxypropyl-beta-cyclodextrin and purification methods | |
| EP4308703A4 (en) | POLYNUCLEOTIDE COMPOSITIONS, RELATED FORMULATIONS AND METHODS OF USE THEREOF | |
| EP4463469A4 (en) | DESIGNED CYTOKIN COMPOSITIONS AND METHODS OF ADMINISTRATION | |
| EP4117654C0 (en) | Compositions for the treatment of infections and for the interruption of biofilm formation | |
| EP4157328A4 (en) | COMPOSITIONS AND METHODS FOR INHIBITING PROLIFERATION OF VASCULAR SMOOTH MUSCLE CELLS | |
| EP4100430A4 (en) | COMPOSITIONS AND METHODS FOR TREATMENT OF PULMONARY HYPERTENSION | |
| EP4297726A4 (en) | INJECTABLE FORMULATION OF SODIUM BICARBONATE AND METHODS OF USE THEREOF | |
| EP4181689A4 (en) | COMPOSITION OF TASTE ENHANCER | |
| EP4251199A4 (en) | METHODS AND COMPOSITIONS FOR THE TREATMENT OF VIRAL INFECTION | |
| EP4203939A4 (en) | COMPOSITIONS AND METHODS OF ADMINISTRATION OF LEVODOPA | |
| EP4132470A4 (en) | COMPOSITIONS AND METHODS FOR TREATMENT AND PREVENTION OF LUNG DISEASE | |
| EP4203946A4 (en) | CANNABINOID FORMULATIONS AND METHODS OF USE | |
| EP4251168A4 (en) | COMPOSITIONS COMPRISING FLUMAZENIL AND NALTREXONE AND METHODS OF USE THEREOF | |
| EP4232569A4 (en) | COMPOSITIONS AND METHODS OF RNA SYNTHESIS | |
| EP4346802A4 (en) | COMPOSITIONS AND METHODS OF TREATMENT OF HYPERTENSION | |
| EP4153617A4 (en) | PREPARATION AND PURIFICATION OF HYPERSIALYLATED IGG | |
| EP4284443A4 (en) | METHODS OF SYNTHESIS AND COMPOSITIONS OF WEAK INTERMEDIATE CONTRAST AGENTS AND WEAK DICHELATE INTERMEDIATE CONTRAST AGENTS |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: UNKNOWN |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
| 17P | Request for examination filed |
Effective date: 20230523 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
| RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: BUNKA, ANDREW Inventor name: DOCHERTY, JOHN |
|
| A4 | Supplementary search report drawn up and despatched |
Effective date: 20240731 |
|
| RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61K 9/14 20060101ALI20240725BHEP Ipc: A24B 13/00 20060101ALI20240725BHEP Ipc: A24B 15/28 20060101ALI20240725BHEP Ipc: A61K 31/465 20060101ALI20240725BHEP Ipc: A61K 9/00 20060101ALI20240725BHEP Ipc: A24B 15/16 20200101ALI20240725BHEP Ipc: A24B 15/30 20060101ALI20240725BHEP Ipc: A24B 15/10 20060101ALI20240725BHEP Ipc: A24B 15/18 20060101AFI20240725BHEP |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
| 17Q | First examination report despatched |
Effective date: 20250409 |
|
| DAV | Request for validation of the european patent (deleted) | ||
| DAX | Request for extension of the european patent (deleted) | ||
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
| 18D | Application deemed to be withdrawn |
Effective date: 20250812 |